Suppression of tumor necrosis factor secretion from white blood cells by synthetic antisense phosphorothioate oligodeoxynucleotides
Journal
International Journal of Immunopharmacology
Journal Volume
22
Journal Issue
6
Pages
445-452
Date Issued
2000
Author(s)
Chu S.-H.
Abstract
In this ex vivo, rather than in vitro, experiment, a synthetic antisense oligodeoxynucleotide was tested to suppress tumor necrosis factor - α(TNF) secretion from lipopolysaccharide-stimulated white blood cells. Antisense oligomer showed significant and specific suppressive effect to the secretion of TNF at concentrations of 1.0 and 10 μM. At the concentration of 1 μM, there were 68.4 and 63.9% suppression of TNF secretion at 2 and 24 h after resuspension of blood cells. At the concentration of 10 μM, the suppressions were slightly higher than those at 1 μM, which were 71.8 and 76.2%, respectively. A 50%-matched scrambler showed suppressive effect only at 10 μM concentration, and the suppression only occurred at 2 and 24 h after incubation. Sense oligomer showed no suppressive effects at any of the concentrations. The specificity of this oligomer was documented by dose- effect phenomenon, sequence-dependent suppression and absence of effect on the synthesis of another cytokine (interleukin-6). A series of parallel studies was performed and showed that all three oligomers at any concentration tested had no effect on the interleukin-6 secretion after LPS stimulation. In conclusion, properly designed antisense oligodeoxynucleotide can significantly and specifically suppress the secretion of TNF by blood cells in an ex vivo system and it may be a good 'information' drug to treat diseases that are caused by over production of TNF. (C) 2000 International Society for Immunopharmacology.
SDGs
Other Subjects
antisense oligodeoxynucleotide; interleukin 6; lipopolysaccharide; oligodeoxynucleotide phosphorothioate; tumor necrosis factor alpha; article; blood culture; controlled study; cytokine release; dose response; human; human cell; leukocyte; priority journal; protein synthesis inhibition; regulatory mechanism; sepsis; Cycloheximide; Humans; Interleukin-6; Leukocytes; Lipopolysaccharides; Oligonucleotides, Antisense; Protein Synthesis Inhibitors; Stimulation, Chemical; Tumor Necrosis Factor-alpha
Type
journal article